APA (7th ed.) Citation

JH, F., LS, E., & JS, S. (2025). Nirsevimab: Expansion of Respiratory Syncytial Virus Prevention Options in Neonates, Infants, and At-Risk Young Children. The Annals of pharmacotherapy, 59(1), 81. https://doi.org/10.1177/10600280241243357

Chicago Style (17th ed.) Citation

JH, Fly, Eiland LS, and Stultz JS. "Nirsevimab: Expansion of Respiratory Syncytial Virus Prevention Options in Neonates, Infants, and At-Risk Young Children." The Annals of Pharmacotherapy 59, no. 1 (2025): 81. https://doi.org/10.1177/10600280241243357.

MLA (9th ed.) Citation

JH, Fly, et al. "Nirsevimab: Expansion of Respiratory Syncytial Virus Prevention Options in Neonates, Infants, and At-Risk Young Children." The Annals of Pharmacotherapy, vol. 59, no. 1, 2025, p. 81, https://doi.org/10.1177/10600280241243357.